Last reviewed · How we verify
Induction- PF-06480605 50 mg SC Q4W — Competitive Intelligence Brief
phase 2
Live · refreshed every 30 min
Target snapshot
Induction- PF-06480605 50 mg SC Q4W (induction-pf-06480605-50-mg-sc-q4w) — Pfizer Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Induction- PF-06480605 50 mg SC Q4W TARGET | induction-pf-06480605-50-mg-sc-q4w | Pfizer Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Induction- PF-06480605 50 mg SC Q4W CI watch — RSS
- Induction- PF-06480605 50 mg SC Q4W CI watch — Atom
- Induction- PF-06480605 50 mg SC Q4W CI watch — JSON
- Induction- PF-06480605 50 mg SC Q4W alone — RSS
Cite this brief
Drug Landscape (2026). Induction- PF-06480605 50 mg SC Q4W — Competitive Intelligence Brief. https://druglandscape.com/ci/induction-pf-06480605-50-mg-sc-q4w. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab